Dr. Schayowitz, PhD, MBA is an Operating Partner at EcoR1 Capital LLC, a biotech-focused investment advisory firm which invests in companies at all stages of research and development. With nearly 20 years of oncology drug development experience, Dr. Schayowitz has led dozens of global development programs from initiation through approval and commercialization. Prior to joining EcoR1, he was a Vice President at Pfizer Oncology with various development leadership roles across breast cancer, prostate cancer, colorectal cancer and melanoma, ultimately culminating in the Head of Product Development Teams for Pfizer Oncology. Prior to Pfizer, Dr. Schayowitz, led the development of Zejula (niraparib) at Tesaro, and was a member of the Medical Affairs leadership team at Algeta supporting the commercialization of Xofigo (Radium-223). He also serves as a Board Observer for Aktis Oncology.

Dr. Schayowitz has a Bachelor of Arts from Hamilton College, a PhD in Pharmacology from The University of Maryland and an MBA from Johns Hopkins.